StockData
Gossamer Bio, Inc. logo

Gossamer Bio, Inc. (GOSS) stock

GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$11.43+0.39 (+3.53%)

Close on Nov 18, 2026Market cap $5.59BP/E –Yield –

Gossamer Bio revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Gossamer Bio's revenue for the twelve months ending Jun 30, 2026 was $53.29M, up 32.4% year over year. For fiscal 2025 it was $48.47M, down 57.7% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$48.47M-57.7%
FY2024Dec 31, 2024$114.70M–
FY2023Dec 31, 2023$0–
FY2022Dec 31, 2022$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$9.24M-19.6%
Q1 FY2026Mar 31, 2026$16.96M+71.5%
Q4 FY2025Dec 31, 2025$13.80M+47.1%
Q3 FY2025Sep 30, 2025$13.29M+40.2%
Q2 FY2025Jun 30, 2025$11.49M-88.0%
Q1 FY2025Mar 31, 2025$9.89M–
Q4 FY2024Dec 31, 2024$9.38M–
Q3 FY2024Sep 30, 2024$9.48M–
Q2 FY2024Jun 30, 2024$95.84M–
Q1 FY2024Mar 31, 2024$0–
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023$0–
Q2 FY2023Jun 30, 2023$0–

More Gossamer Bio figures

See a number that looks wrong?